Access to Information Requests Completed - February 2015

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the month of February 2015
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2012-01606 Documents related to Risperdal (Risperidone) and Risperdal Consta manufactured by Janssen Inc., correspondence between Janssen Inc. and Health Canada, and copy of materiel provided to physicians by Janssen Inc. representatives. Disclosed in part 472
A-2013-00037 Documents on any tests that have measured nicotine and/or other substances in e-cigarettes and/or in emissions of e-cigarettes (Jan 1, 2009 to Apr 15, 2013) Disclosed in part 2 086
A-2013-00827 Documents pertaining to the decision to transfer the Canadian Food Inspection Agency and/or Food Inspection to Health Canada Disclosed in part 12
A-2013-01057 Documents related to tuberculosis in First Nations communities (Dec 3, 2012 to Dec 3, 2013) Disclosed in part 664
A-2013-01253 Information provided by PROCTOR & GAMBLE and correspondence between PROCTOR & GAMBLE and Health Canada concerning ALIGN (probiotic supplement) Disclosed in part 409
A-2013-01278 Documents from presentations at the Expert Product Advisory Committee on the Vigilance of Health Products meeting in Ottawa
  • Post-market surveillance strategy
  • Off-label use of therapeutic products
  • Mind the Gap: Therapeutic Products for Infants, Children and Youth
  • Post-Market Challenges Related to Off-Label Use: Avastin Case Study
  • Case Study: Quinine and Off-Label Use for Leg Cramps
  • Challenges Associated with Off-Label Advertising: Avastin and Quinine
(May 31 to Jun 2, 2011)
Disclosed in part 112
A-2013-01279 Documents from presentations at the Expert Product Advisory Committee on the Vigilance of Health Products meeting in Ottawa:
  • Off-Label Use of Prescription Drugs: Patient Perspective
  • Patient/Consumer Perspective on Off-Label Use: Anti-psychotic Drugs to Treat Dementia
  • Off-Label Use of Medications: Clinical Practice Perspective
  • Off-Label Use of Marketed Medications: Clinical Practice Perspective
  • Off-Label Uses: Legal and Ethical Issues
(May 31 to Jun 2, 2011
Disclosed in part 112
A-2013-01403 Information related to the Office of Controlled Substances database description such as its logical organization, its intended function, its origin and history, the cost of maintenance of the database, its legal standing, and how the database is explained to media and other individuals. Disclosed in part 63
A-2013-01405 Request to view the Office of Controlled Substances database in its native form . All disclosed 1
A-2014-00164 All documentation on health and safety risks posed by licensed growers under the Medical Marihuana Access Regulations, including concerns about abuse of the system (Jan. 1, 2012 to May 1, 2014) Disclosed in part 863
A-2014-00402

Adverse Reaction Report (AER) for the following products/report numbers: 000505834,E2B_00001940, 000528204, E2B_00002859, 000534628, E2B_00009500, 000540868, E2B_00015395, 000545774 and E2B_00000193

Disclosed in part 126
A-2014-00574 Documents received from BIOTECanada, and communications between Health Canada and BIOTECanada representatives, pertaining to subsequent entry biologics (SEBs), biosimilars, or follow on biologics. Disclosed in part 81
A-2014-00677 Correspondence created or transmitted to the Minister of Health or her office, concerning electronic cigarettes (Mar 4 to Sep 4, 2014) All disclosed 10
A-2014-00719 Information regarding the supply and availability of medical marihuana within the Marihuana for Medical Purposes Regulations (MMPR) and how the responses to MMPR inquiries within Health Canada are handled, especially with regards to Peace Naturals. Disclosed in part 85
A-2014-00730 Information for the following licensed producer under the Marihuana for Medical Purposes Regulations: Bedrocan Canada Inc., Canna Farms Ltd., CanniMed Ltd., Delta 9 Bio-Tech Inc., In The Zone Produce Ltd., Mettrum Ltd., MedReleaf Corp., OrganiGram Inc., The Peace Naturals Project Inc, ThunderBird Biomedical Inc., Tilray Tweed Inc., Whistler Medical Marijuana Corp. The information requested: total patients registered, total grams produced, total grams sold, total grams stored, monthly revenue. (Oct 1, 2013 to Sep 1, 2014) Disclosed in part 815
A-2014-00760 Information related to the time it took for the security clearances of all licensed producers to be completed by Health Canada. Disclosed in part 1
A-2014-00840 Documents pertaining to the Consumer Product Complaints with respect to incidents involving Wired Glass or Georgian Polished Wired Glass, causing personal injuries (Jan 1, 2009 to Jan 20, 2015) No records exist 0
A-2014-00893 All correspondence between Health Canada and Alberta Health on the Copeman Healthcare Centre (Jan 1, 2012 to Nov 3, 2014) All disclosed 8
A-2014-00894 All correspondence between Health Canada and Alberta Health on Preventous Collaborative Health
(Jan 1, 2012 to Nov 3, 2014)
All disclosed 3
A-2014-00918 Adverse Reaction Report (AER) for Taxotere (docetaxel). Report number: E2B_00065281. Disclosed in part 20
A-2014-00922 Adverse Reaction Report (AER) for Arava (leflunomide). Report number: E2B_00002808. Disclosed in part 13
A-2014-00942 Adverse Reaction Report (AER) for DAXAS (roflumilast). Report number: E2B_00092919. All disclosed 13
A-2014-00944 Adverse Reaction Report (AER) for TECTA. Report numbers: 000582376; 000584001; 000584553; 000588426; 000596270; 000596766; 000606117; 000606578; 000610398; 000612522; 000614103; E2B_00098697. Disclosed in part 34
A-2014-00948 Adverse Reaction Report (AER) for LUPRON. Report numbers: 000604443, 000610676, and 000609828. Disclosed in part 26
A-2014-00950 Adverse Reaction Report (AER) for KALETRA. Report numbers: 000605111, 000604323 and 000607821. Disclosed in part 13
A-2014-00951 Adverse Reaction Report (AER) for HUMIRA. Report numbers: 000611956 and 000608861. Disclosed in part 6
A-2014-00970 Adverse Reaction Report (AER) for Arava (leflunomide). Report number: E2B_00000398. Disclosed in part 25
A-2014-00975 Adverse Reaction Report (AER) for CERVARIX. Report numbers: 000368664, 000389266, 000402227, 000408727, 000526805, 000562079, 000573187, 000602019, and 000613936). Disclosed in part 40
A-2014-00976 Adverse Reaction Report (AER) for Human Papillomavirus (HPV) Vaccine. Report numbers: 000406575, 000415934, 000416090, 000422901, 000444259, and 000509867). Disclosed in part 13
A-2014-00978 Adverse Reaction Report (AER) for Gardasil. Report numbers: 000387696, 000396733, 000397781, 000404683, 000410120, 000411615, 000412603, 000425690, 000427447, 000433158, 000437034, 000438175, 000439568, 000445637, 000448900, 000449128, 000457789, 000457935, 000460512, 000468787. Disclosed in part 36
A-2014-01019 Documents pertaining to Health Canada's environmental inspection relating to the living unit of Warkworth Institution (Campbellford, ON) Unit 2
(Jan 1, 2000 to Dec 31, 2003)
All disclosed 6
A-2014-01041 Adverse Reaction Report (AER) for Plavix (Clopidogrel). Report number: E2B_00109876. All disclosed 9
A-2014-01045 Copy of briefing notes and memoranda:
  • 13-114993-219 : Health Promotion and Drug Prevention Strategy for Canada's Youth, Nov 18/2013 (DMO-MBU)
  • 13-113701-733 : Mental Health Commission of Canada 2012-13 annual report tabling to Parliament Jan 2014 (SPB)
  • 13-113248-216 : Internal Meeting on First Nations and Inuit Health Role (DMO-MBU)
  • 13-114251-41 : Key Ministerial Engagements for 2013-14 (PHAC-SPPIA)
  • 13-112732-934 : MO verbal briefing on International Engagement (PHAC-SPPIA)
  • 13-113136-295 : Ministerial Briefing on Neurological Diseases and Dementia (PHAC-SPPIA)
  • 13-113258-206 : Health Portfolio input provided to AANDC on Canadian High-Arctic Research Station (DMO-MBU)
  • 13-114182-749 : Alberta Suicide Prevention Strategy (PHAC-HPCDP)
Disclosed in part 16
A-2014-01048 Adverse Reaction Report (AER) for Synthroid. Report numbers: E2B_00105165, E2B_00105165, E2B_00083080, E2B_00082517 and 000610107. Disclosed in part 54
A-2014-01051 Adverse Reaction Report (AER) for Rythmol. Report number: E2B_00091511. Disclosed in part 54
A-2014-01053 Adverse Reaction Report (AER) for Perindopril. Report numbers: 000614143 and E2B_00083043. Disclosed in part 46
A-2014-01058 Notice of Compliance with conditions (NOC/c) for Novo-Atorvastatin (Atorvastatin Calcium) 10,20,40 and 80 mg by Novopharm Limited. (NOC/c prior to May 19, 2010). Disclosed in part 2
A-2014-01066 Notice of Compliance with conditions (NOC/c) for (Atorvastatin (Atorvastatin Calcium) 10, 20, 40 and 80 mg by Avanstra Inc. (NOC/c prior to Nov 4, 2011). Disclosed in part 1
A-2014-01067 Notice of Compliance with conditions (NOC/c) for Mylan-Atorvastatin (Atorvastatin Calcium) 10, 20, 40 and 80 mg by Mylan Pharmaceuticals ULC. (NOC/c prior to October 14, 2011). Disclosed in part 1
A-2014-01068 Notice of Compliance with conditions (NOC/c) for Ran-Atorvastatin (Atorvastatin Calcium) 10, 20, 40 and 80 mg by Ranbaxy Pharmaceuticals Canada Inc. (NOC/c prior to May 20, 2010). Disclosed in part 1
A-2014-01070 Notice of Compliance with conditions (NOC/c) for Atorvastatin (Atorvastatin Calcium) 10,20,40 and 80 mg by Sandoz Canada Inc. (NOC/c prior to May 19, 2010). Disclosed in part 2
A-2014-01071 Notice of Compliance with conditions (NOC/c) for Atorvastatin (Atorvastatin Calcium) 10, 20, 40 and 80 mg by Cobalt Pharmaceuticals Company. (NOC/c prior to May 19, 2010). Disclosed in part 1
A-2014-01073 Notice of Compliance with conditions (NOC/c) for Atorvastatin (Atorvastatin Calcium) 10,20,40 and 80 mg by Ratiopharm Inc. (NOC/c prior to May 19, 2010). Disclosed in part 2
A-2014-01075 Notice of Compliance with conditions (NOC/c) for Atorvastation (Atorvastatin supplied as Atorvastatin Calcium) 10,20,40 and 80 mg by Sanis Health Inc. (NOC/c prior to May 19, 2010) Disclosed in part 2
A-2014-01076 Notice of Compliance with conditions (NOC/c) for Atorvastation Calcium (Atorvastatin Calcium) 10, 20, 40 and 80 mg by Dr. Reddy's Laboratoires Limited. (NOC/c prior to December 23, 2013). Disclosed in part 2
A-2014-01077 Notice of Compliance with conditions (NOC/c) for Atorvastation 10, 20, 40 and 80 mg by Teva Canada Limited. (NOC/c prior to July 19, 2013). Disclosed in part 2
A-2014-01087 Documents pertaining to the Health Canada wind turbine noise and health study summary of results released on or about November 6, 2014. No records exist 0
A-2014-01094 Documents pertaining to the wind turbine noise and health study held on or about November 6, 2014 and beyond for criteria established to determine the identified stakeholder organisations, a list of stakeholder organisations attending meetings, list of participants, meeting notes and correspondence. Disclosed in part 102
A-2014-01115 Documents pertaining to the new drug submission of VICOPROFEN HYDROCODONE BITARTRATE, IBURPROFEN), DIN 02242018 NDS submitted by KNOLL PHARMA INC. approved by Health Canada on 11 April 2000. All exempted 0
A-2014-01169 Documents pertaining to all post-campaign assessments of the Preventing Illicit Drug Use mass media campaign (Oct 20, 2014 to Dec 28, 2014) Disclosed in part 254
A-2014-01198 Documents pertaining to the total number of Loss and Theft Report Form, with material and quantities taken reported to Health Canada's Office of Controlled Substances from Hamilton, Dundas, Ancaster and Stoney Creek (Jan 1, 2010 to Dec 31, 2014) All disclosed 34
A-2014-01200 All contracts processed in the National Capital Region under the terms of the ANY Standing Offer for temporary help services or Supply Arrangement for Task and Solutions Professional Services (TSPS) and for Task-Based Informatics Professional Services (TBIPS) during the months of April to November 2014. All disclosed 19
A-2014-01204 Information pertaining to contract / requisition No. H3551-123194 (Nursing Services) relating to:
  • The total cost of work requested by Canada from each company;
  • The total value of all signed Task Authorizations (TAs) issued to each company reflecting the actual cost of nursing services and travel; and,
  • The total actual cost of work provided by each company reflecting the actual cost of nursing services and travel.
(Nov 1, 2013 to Apr 30, 2014 and May 1, 2014 to Oct 31, 2014)
Disclosed in part 36
A-2014-01207 Briefing material to or by the Deputy Minister of Health Canada regarding the Cargill Meat Solutions beef recall in November and December 2014 No records exist 0
A-2014-01208 Listing of the Access to Information (ATI) requests submitted to Health Canada, including the request number, the source of the requester, the date of the request and a description of the request. (Dec 1, 2014 to Dec 31, 2014) Disclosed in part 0
A-2014-01213 Documents pursuant to the Marihuana for Medical Purposes Regulations (MMPR) for licensed producers and related to policies and procedures. Disclosed in part 86
A-2014-01220 Adverse Reaction Report (AER) for the following products/report numbers: Feraheme (Ferumoxytol) (000614259, 000619950, 000620132, 000622227, 000626431, 000627552); Omnaris (Ciclesonide) (000622354); Ondissolve (Ondansetron) (000622965) Disclosed in part 10
A-2014-01232 Information related to the Health Canada's decision to consider Disulfiram Tablets as a new drug. Reference to a 1984 letter to ICN Canada Limited of Montreal. No records exist 0
A-2014-01234 List (as of December 31, 2014) of all Marihuana Produces who have applied under the Marihuana for Medical Purposes Regulations that have yet to be approved or have been refused. Disclosed in part 16
A-2014-01243 Adverse Reaction Report (AER) for TD Adsorbed Vaccine. Report number: 000605563. Disclosed in part 1
A-2014-01244 Adverse Reaction Report (AER) for Adacel Vaccine. Report number: 000607250. Disclosed in part 1
A-2014-01245 Adverse Reaction Report (AER) for Tubersol Vaccine. Report number: 000616951. Disclosed in part 3
A-2014-01246 Adverse Reaction Report (AER) for Eloxation (Oxaliplatin). Report number: 000594820. Disclosed in part 1
A-2014-01255 Documents related to the amounts of the substance SODIUM DICHLOROACETATE (NaDCA) authorized by the Special Access Programme of Health Canada for clinical use to medical practitioners in Ontario in 2014. No records exist 0
A-2014-01257 Adverse Reaction Report (AER) for Thallous Chloride T1201. Report number: 000320425. Disclosed in part 1
A-2014-01258 Adverse Reaction Report (AER) for Ultratag RBC. Report number: 000314385. Disclosed in part 1
A-2014-01259 Adverse Reaction Report (AER) for Technetium tc 99m sestamibi. Report number: 000618805. Disclosed in part 1
A-2014-01260 Adverse Reaction Report (AER) for Methadose/Methadone. Report numbers: 000625917; 000615958; 000620162; 000620849; 000623453; 000626411; 000609471; 000612516; 000612826; 000591377; 000591832; 000592815; 000596108. Disclosed in part 20
A-2014-01262 Adverse Reaction Report (AER) for Optimark. Report number: 000341806. Disclosed in part 1
A-2014-01264 All documents pertaining to the issue of exempted codeine products marketed in Canada (drugs containing 8 mg of codeine that can be sold without prescription) exchanged between Health Canada and interested stakeholders such as National Association of Pharmacy Regulatory authorities and pharmaceutical industry representatives. (Nov 1, 2001 to Dec 31, 2002) No records exist 0
A-2014-01273 All documents regarding the 2012 Health Canada audit on Resolve Research Solutions Inc. No records exist 0
A-2014-01277 Adverse Reaction Report (AER) for Quadracel. Report number: 000620704. Disclosed in part 1
A-2014-01281 Adverse Reaction Report (AER) for Synthroid. Report number: 000620549. Disclosed in part 2
A-2014-01282 Adverse Reaction Report (AER) for Biaxin. Report numbers: 000624757 and 000614251. Disclosed in part 3
A-2014-01290 Correspondence relating to effects or complaints against the use of Gardasil (Jul 1, 2014 to Jan 28, 2015) All disclosed 26
A-2014-01292 All communications of James McNamee regarding Private Members Bill C-648 "Warning Labels for Radio Apparatus Act" commonly called the cell phone labelling bill, including press conference held by Member of Parliament Terence Young and Canadians for Safe Technology on January 19, 2015. (Dec 1, 2013 to Jan 22, 2015) No records exist 0
A-2014-01294 All communications of James McNamee regarding the production of Health Canada fact sheet "What is Safety Code 6" number 2014-023, dated Feb 20, 2014 (Dec 1, 2013 to Jan 22, 2015) No records exist 0
A-2014-01295 All communications of James McNamee regarding his appointment to the World Health Organization (WHO) Expert Group on the Environmental Health Criteria Monograph on Radio-frequency Fields (EH-RF), including communications with WHO personnel. (Apr 1, 2014 to Jan 22, 2015) No records exist 0
A-2014-01304 Adverse Reaction Report (AER) for NORVIR. Report numbers: 000619223 and 000619228. Disclosed in part 4
A-2014-01307 Adverse Reaction Report (AER) for LUPRON. Report number: 000624381. Disclosed in part 1
A-2014-01311 Adverse Reaction Report (AER) for report number: E2B 00147001. Disclosed in part 19
A-2014-01314 Adverse Reaction Report (AER) for report number: 000614639. Disclosed in part 1
A-2014-01329 Information on experts reviewing feedback from Safety Code 6 Public Consultation, their qualifications, results of meetings related to the scientific literature on biological effects, and contracts work relating to evaluation of the submissions. (July 15, 2014) No records exist 0
A-2014-01332 List of references which James McNamee referred to in the 3 binders he used during his testimony at the City of Chateauguay court hearings on the Roger's proposed cell tower siting in about February 2012. All disclosed 3
A-2014-01344 Documents pertaining to the possible existence of the practice of female genital mutilation (FGM) specifically in Canada. (Jan 1, 2011 to Jan 28, 2015) No records exist 0
A-2014-01347 Correspondence for the Minister, Deputy Minister or Assistant Deputy Minister related to the Nutrition North Program or correspondence that mentions the issue of food security in the Arctic. (Oct 1, 2014 to Feb. 4, 2015) No records exist 0
A-2014-01354 Documents related to the Quality Assurance Manual (QAM) and all associated Standard Operating Procedures (SOP) in support of Drug Analysis Service Labs regulated by Health Canada and in support of the Controlled Drugs and Substances Act and Regulations No records exist 0
A-2014-01373 Documents relating to expiration of the patent for the Cialis medication in Canada All excluded 0
Report a problem or mistake on this page
Please select all that apply:

Privacy statement

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: